Sara Lodi1, Nneka I Emenyonu2, Kara Marson2, Dalsone Kwarisiima3, Robin Fatch2, Michael G McDonell4, Debbie M Cheng5, Harsha Thirumurthy6, Monica Gandhi2, Carol S Camlin7, Winnie R Muyindike8,9, Judith A Hahn2, Gabriel Chamie2. 1. Department of Biostatistics, Boston University School of Public Health, 801 Massachusetts Avenue, Boston, MA, 02118, USA. slodi@bu.edu. 2. Division of HIV, Infectious Disease and Global Medicine, University of California San Francisco, San Francisco, USA. 3. Infectious Diseases Research Collaboration, Kampala, Uganda. 4. Elson S. Floyd College of Medicine, Washington State University, Spokane, USA. 5. Department of Biostatistics, Boston University School of Public Health, 801 Massachusetts Avenue, Boston, MA, 02118, USA. 6. Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA. 7. Department of Obstetrics, Gynecology & Reproductive Sciences, University of California San Francisco, San Francisco, USA. 8. Global Health Collaborative, Mbarara University of Science and Technology, Mbarara, Uganda. 9. Mbarara Regional Referral Hospital, Mbarara, Uganda.
Abstract
BACKGROUND: The risk of tuberculosis (TB) is high among people with HIV (PWH). Heavy alcohol drinking independently increases TB risk and approximately 25% of PWH globally engage in heavy drinking. While isoniazid (INH) preventive therapy decreases TB incidence and mortality among PWH, heavy drinking during INH is associated with liver toxicity and poor adherence. Interventions are, therefore, urgently needed to decrease alcohol use and improve adherence to INH in this population in settings with high prevalence of HIV and TB like Uganda. METHODS: The Drinkers' Intervention to Prevent TB (DIPT) study is a 2×2 factorial randomized controlled trial among HIV/TB co-infected adults (≥18 years) who engage in heavy alcohol drinking and live in Uganda. The trial will allocate 680 participants with a 1:1:1:1 individual randomization to receive 6 months of INH and one of the following interventions: (1) no incentives (control), (2) financial incentives contingent on low alcohol use, (3) financial incentives contingent on high adherence to INH, and (4) escalating financial incentives for both decreasing alcohol use and increasing adherence to INH. Incentives will be in the form of escalating lottery-based monetary rewards. Participants will attend monthly visits to refill isoniazid medications, undergo liver toxicity monitoring, and, except for controls, determine eligibility for prizes. We will estimate (a) the effect of incentives contingent on low alcohol use on reduction in heavy drinking, measured via a long-term objective and self-reported metric of alcohol use, at 3- and 6-month study visits, and (b) the effect of incentives contingent on high adherence to INH, measured as >90% pill-taking days by medication event monitoring system cap opening. We will use qualitative methods to explore the mechanisms of any influence of financial incentives on HIV virologic suppression. DISCUSSION: This study will provide new information on low-cost strategies to both reduce alcohol use and increase INH adherence among people with HIV and TB infection who engage in heavy drinking in low-income countries with high HIV and TB prevalence. TRIAL REGISTRATION: ClinicalTrials.gov NCT03492216 . Registered on April 10, 2018.
RCT Entities:
BACKGROUND: The risk of tuberculosis (TB) is high among people with HIV (PWH). Heavy alcohol drinking independently increases TB risk and approximately 25% of PWH globally engage in heavy drinking. While isoniazid (INH) preventive therapy decreases TB incidence and mortality among PWH, heavy drinking during INH is associated with liver toxicity and poor adherence. Interventions are, therefore, urgently needed to decrease alcohol use and improve adherence to INH in this population in settings with high prevalence of HIV and TB like Uganda. METHODS: The Drinkers' Intervention to Prevent TB (DIPT) study is a 2×2 factorial randomized controlled trial among HIV/TB co-infected adults (≥18 years) who engage in heavy alcohol drinking and live in Uganda. The trial will allocate 680 participants with a 1:1:1:1 individual randomization to receive 6 months of INH and one of the following interventions: (1) no incentives (control), (2) financial incentives contingent on low alcohol use, (3) financial incentives contingent on high adherence to INH, and (4) escalating financial incentives for both decreasing alcohol use and increasing adherence to INH. Incentives will be in the form of escalating lottery-based monetary rewards. Participants will attend monthly visits to refill isoniazid medications, undergo liver toxicity monitoring, and, except for controls, determine eligibility for prizes. We will estimate (a) the effect of incentives contingent on low alcohol use on reduction in heavy drinking, measured via a long-term objective and self-reported metric of alcohol use, at 3- and 6-month study visits, and (b) the effect of incentives contingent on high adherence to INH, measured as >90% pill-taking days by medication event monitoring system cap opening. We will use qualitative methods to explore the mechanisms of any influence of financial incentives on HIV virologic suppression. DISCUSSION: This study will provide new information on low-cost strategies to both reduce alcohol use and increase INH adherence among people with HIV and TB infection who engage in heavy drinking in low-income countries with high HIV and TB prevalence. TRIAL REGISTRATION: ClinicalTrials.gov NCT03492216 . Registered on April 10, 2018.
Authors: R Scott Braithwaite; Kathleen A McGinnis; Joseph Conigliaro; Stephen A Maisto; Stephen Crystal; Nancy Day; Robert L Cook; Adam Gordon; Michael W Bridges; Jason F S Seiler; Amy C Justice Journal: Alcohol Clin Exp Res Date: 2005-07 Impact factor: 3.455
Authors: Jussi J Saukkonen; David L Cohn; Robert M Jasmer; Steven Schenker; John A Jereb; Charles M Nolan; Charles A Peloquin; Fred M Gordin; David Nunes; Dorothy B Strader; John Bernardo; Raman Venkataramanan; Timothy R Sterling Journal: Am J Respir Crit Care Med Date: 2006-10-15 Impact factor: 21.405
Authors: Christian S Hendershot; Susan A Stoner; David W Pantalone; Jane M Simoni Journal: J Acquir Immune Defic Syndr Date: 2009-10-01 Impact factor: 3.731
Authors: Sameer Imtiaz; Kevin D Shield; Michael Roerecke; Andriy V Samokhvalov; Knut Lönnroth; Jürgen Rehm Journal: Eur Respir J Date: 2017-07-13 Impact factor: 16.671
Authors: Jürgen Rehm; Andriy V Samokhvalov; Manuela G Neuman; Robin Room; Charles Parry; Knut Lönnroth; Jayadeep Patra; Vladimir Poznyak; Svetlana Popova Journal: BMC Public Health Date: 2009-12-05 Impact factor: 3.295
Authors: Jonathan E Golub; Paul Pronyk; Lerato Mohapi; Nkeko Thsabangu; Mosa Moshabela; Helen Struthers; Glenda E Gray; James A McIntyre; Richard E Chaisson; Neil A Martinson Journal: AIDS Date: 2009-03-13 Impact factor: 4.177
Authors: Knut Lönnroth; Brian G Williams; Stephanie Stadlin; Ernesto Jaramillo; Christopher Dye Journal: BMC Public Health Date: 2008-08-14 Impact factor: 3.295
Authors: Neo K Morojele; Sheela V Shenoi; Paul A Shuper; Ronald Scott Braithwaite; Jürgen Rehm Journal: Nutrients Date: 2021-09-23 Impact factor: 5.717
Authors: Amanda P Miller; Robin Fatch; Sara Lodi; Kara Marson; Nneka Emenyonu; Allen Kekibiina; Brian Beesiga; Gabriel Chamie; Winnie R Muyindike; Judith A Hahn Journal: BMC Public Health Date: 2022-10-10 Impact factor: 4.135